Lawrence Karsh, MD, FACS

No bio available.

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Scientific Study or Trial (Oncology)
    Ineligible company: 
    Veru Pharmaceuticals
    Mitigation strategy: 
    Divest
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Scientific Study or Trial (Oncology)
    Ineligible company: 
    NeoGenomic Laboratories
    Mitigation strategy: 
    Divest
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    EMD Serono
    Mitigation strategy: 
    Divest
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Scientific Study or Trial (Oncology)
    Ineligible company: 
    Minomic
    Mitigation strategy: 
    Divest
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Scientific Study or Trial (Oncology)
    Ineligible company: 
    Nucleix
    Mitigation strategy: 
    Divest
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Scientific Study or Trial (Oncology)
    Ineligible company: 
    Siemans
    Mitigation strategy: 
    Divest
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Scientific Study or Trial (Oncology)
    Ineligible company: 
    Cepheid
    Mitigation strategy: 
    Divest
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Arivan Research
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Pfizer
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Myovant
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    09/20/2022

Pages

Return to 2022 AUA Annual Meeting Highlights: Prostate Cancer